pocketful logo
Alkem Laboratories Ltd logo

Alkem Laboratories Ltd

NSE: ALKEM BSE: 539523

₹5402.50

(-7.97%)

Sat, 14 Feb 2026, 07:59 am

mtf coin illustrationMTF 5x

Alkem Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    64583.63

  • Net Profit

    2216

  • P/B

    4.87

  • Sector P/E

    32.04

  • P/E

    26.94

  • EV/EBITDA

    19.35

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    16.31

  • ROCE (Industry)

    15.98

  • RONW (Industry)

    14.01

  • ROE

    19.88

  • ROCE

    20.03

  • Debt/Equity

    0.13

  • EPS (TTM)

    196.58

  • Dividend Yield

    0.83

  • Book Value

    1116.21

  • Interest Cover

    21.76

Analysis

all

thumbs up icon

Pros

  • Dividends paid are well covered by earnings (3.8x coverage).
  • Dividends after 3 years are expected to be well covered by earnings (4.7x coverage).
  • Alkem Laboratories's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Cash flow for Alkem Laboratories is expected to increase by more than 50% in 2 years time.
  • Alkem Laboratories's earnings growth is expected to exceed the low risk savings rate of 7.2%.
thumbs up icon

Cons

  • Dividend payments have increased, but Alkem Laboratories only paid a dividend in the past 4 years.
  • Alkem Laboratories has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Alkem Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Alkem Laboratories's earnings are expected to grow by 13.5% yearly, however this is not considered high growth (20% yearly).
  • Alkem Laboratories's earnings growth is positive but not above the India market average.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters51.2051.2053.0455.1355.66
FII9.979.489.119.4110.15
DII21.5421.9321.8019.4218.01
Public17.3017.4016.0516.0516.18
Government0000.000.00

Read More

Technical Analysis

RSI

36.02

MACD

3.52

50 DMA

5666.54

200 DMA

5355.61

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic67646214.50594656655396.505115.504566
Fibonacci6214.506004.595874.9156655455.095325.415115.50
Camarilla5828.615778.245727.8756655627.135576.765526.39

Pivots Level: Classic

R3

+1099

6764

R2

+549.50

6214.50

R1

+281

5946

5665
5665
Pivot Point
LTP: 5402.50

S1

-268.50

5396.50

S2

-549.50

5115.50

S3

-1099

4566

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    5698.68

  • 20-EMA

    5700.30

  • 30-EMA

    5693.87

  • 50-EMA

    5672.30

  • 100-EMA

    5589.76

  • 200-EMA

    5456.93

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
13 Feb 2026board-meetingsQuarterly Results, Interim Dividend
13 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
29 May 2025dividend₹8.00 Dividend /Share08 Aug 2025
29 May 2025agm
07 Feb 2025dividend₹37.00 Dividend /Share14 Feb 2025
29 May 2024dividend₹5.00 Dividend /Share10 Aug 2024
29 May 2024agm
09 Feb 2024dividend₹35.00 Dividend /Share17 Feb 2024
19 May 2023dividend₹10.00 Dividend /Share10 Aug 2023
19 May 2023agm

Read More

Peer Comparison

Alkem Laboratories Ltd logo

Alkem Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Alkem Laboratories Ltd About

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical products.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1973

Headquarters

CEO

Basudeo N Singh

Employees

Contact

Website icon

Website

http://www.alkemlabs.com

Email icon

Email

investors@alkem.com ; contact@alkem.com

Phone icon

Phone

91-22-39829999

Location icon

Location

Alkem House SenapatiBapat Marg, Lower Parel, Mumbai, Maharashtra, 400013

Read More

Alkem Laboratories Ltd Company History

YearHistory
2019
  • Alkem crossed the revenue milestone of USD 1 billion.
  • Alkem received the Express Pharma Excellence Award at Pharma CXO Summit 2019.
  • Alkem Laboratories took over an undertaking from Cachet Pharmaceuticals.
2020
  • Alkem launched Favipiravir in India under the brand name 'Alfluenza'.
  • Alkem received the 'Best IT team of the Year' award at the CIO Conclave and Awards 2020.
2021
  • Alkem launched Ibuprofen and Famotidine Tablets in the United States.
  • Alkem launched Perampanel Tablets in India under the brand name 'Perampil'.
  • Alkem launched Brivaracetam in India under the brand name 'Brivasure'.
  • Alkem partnered with Tata Memorial Hospital.
  • Alkem was recognized as one of India's Best Workplaces in Biotechnology & Pharmaceutical Industry for the second consecutive year.
2022
  • Alkem signed a license agreement with Harvard University's Office of Technology Development.
2023
  • The Company entered into a co-development and license agreement with Biosergen AB for the development and commercialization of BSG005.
  • The NCLT approved the Scheme of Amalgamation for the merger of Pharmasofttech Awacs Pvt. Ltd. into Pharmarack Technologies Pvt. Ltd.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
SAMPRADA&NANHAMATI SINGH FAMILY TRUSTSell7554004831.9211 Jun 2025
JAYANTI SINHASell17000004874.6104 Jun 2025
SAMPRADA&NANHAMATI SINGH FAMILY TRUSTSell641712468021 Feb 2025
UBS PRINCIPAL CAPITAL ASIA LIMITEDSell9895065468.9925 Nov 2024
SAMPRADA&NANHAMATI SINGH FAMILY TRUSTSell8500005732.1522 Aug 2024
RAJEEV RANJANSell1000000495018 Jun 2024
RAJESH KUMARSell10000004950.2218 Jun 2024

Read More

Alkem Laboratories Ltd News

Alkem Labs amends Enzene Biosciences agreement

Alkem Laboratories enters Amendment cum Supplemental Agreement with Enzene Biosciences and investors for Rs. 26.16 crore fund infusion through preferential allotment of securities.

13 Feb 2026

co actions results

Alkem Labs to Acquire 51-55% Stake in Swiss Medtech Firm

Alkem Laboratories' subsidiary to acquire majority stake in Occlutech Holding AG, a Swiss cardiovascular device manufacturer, for EUR 180.70 million total equity value.

13 Feb 2026

co actions results

Alkem Labs Reschedules Q3FY26 Results Call to 5 PM

Alkem Laboratories has revised the timing of its Q3FY26 and 9MFY26 financial results conference call to 5:00 PM IST on February 13, 2026, moving it one hour later than originally scheduled.

12 Feb 2026

co actions results

Alkem Labs Board Approves Subsidiary Merger Plan

Alkem Laboratories' board has approved the merger of Alkem Medtech Ortho Private Limited with Alkem Medtech Private Limited, pending NCLT approval and shareholder consent for the corporate restructuring.

06 Feb 2026

co actions results

Alkem Labs Block Trade Worth Rs. 58.81 Crores

Alkem Laboratories witnessed a significant NSE block trade worth Rs. 58.81 crores involving 101,852 shares at Rs. 5774.00 per share, indicating substantial institutional activity.

28 Jan 2026

co actions results

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800